A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
Marc-Eric Halatsch, Richard E. Kast, Georg Karpel-Massler, Benjamin Mayer, Oliver Zolk, Bernd Schmitz, Angelika Scheuerle, Ludwig Maier, Lars Bullinger, Regine Mayer-Steinacker, Carl Schmidt, Katharina Zeiler, Ziad Elshaer, Patricia Panther, Birgit Schmelzle, Anke Hallmen, Annika Dwucet, Markus D. Siegelin, Mike-Andrew Westhoff, Kristine Beckers, Gauthier Bouche, and Tim Heiland. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neuro-Oncology Advances, 3(1), 1–11, 2021, doi.org/10.1093/noajnl/vdab075
Glioblastoma (GBM) is an aggressive type of brain cancer that escapes most drug treatments. Only 15-20% of patients survive more than 5 years with the usual treatment currently available (surgery, radiation, and chemotherapy using temozolomide).
In this study, a treatment regimen with 9 different drugs (CUSP9v3) in addition to low-dose, continuous temozolomide was devised to tackle this issue.
The conclusion is that CUSP9v3 can be safely administered to patients with recurrent GBM.